Epilepsy (treatment Refractory)
Conditions
Keywords
patent foramen ovale, epielpsy
Brief summary
Patent foramen ovale (PFO) is the most common cause of right-to-left shunt (RLS) in the adult heart, with a prevalence of approximately 25% in the general population. Extensive research has demonstrated an association between PFO and neurological conditions such as cryptogenic stroke, migraine, and sleep apnea syndrome, and it is even considered a potential root cause of these disorders. However, the mechanisms by which PFO contributes to neurological diseases remain unclear. In our preliminary clinical work, we have observed a strong correlation between PFO and epilepsy, and PFO closure has shown some efficacy in reducing seizure frequency. The aim of this study is to further investigate the efficacy and safety of PFO closure in patients with drug-resistant epilepsy.
Interventions
patent foramen ovale closure
Sponsors
Sichuan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 18 and 60 years, with no gender restrictions; 2. Diagnosis of epilepsy in accordance with the International League Against Epilepsy (ILAE) criteria (2014 edition); 3. Drug-resistant epilepsy, defined as failure to achieve sustained seizure freedom despite appropriate selection and tolerability of at least two antiseizure medications (monotherapy or combination therapy) for a minimum of six months; 4. Diagnosis of patent foramen ovale (PFO) meeting the criteria established by the American Society of Echocardiography (ASE) and the Society for Cardiovascular Angiography and Interventions (SCAI) (2015 edition), with right-to-left shunting (RLS) of grade II or higher upon Valsalva maneuver, as assessed by contrast-enhanced echocardiography; 5. Stable antiseizure medication regimen for at least four weeks prior to screening, with willingness to maintain a stable regimen throughout the study period; 6. At least one documented seizure episode during a six-week screening period (with a minimum of four weeks of effective seizure diary recordings) and a retrospective self-reported history of at least 12 seizures in the year preceding screening; 7. Ability to independently or with caregiver assistance complete a seizure diary and comply with clinical data collection and required medical examinations; 8. Willingness to undergo the investigational treatment and voluntary provision of written informed consent.
Exclusion criteria
1. Patients diagnosed with epilepsy of a known etiology, including infectious, metabolic, immune, genetic, or structural causes; 2. History of stroke or psychogenic nonepileptic seizures (PNES); 3. History of epilepsy surgery or implantable neurostimulation therapy, or planned epilepsy surgery, neurostimulation therapy, ketogenic diet therapy, or other antiseizure interventions during the study period; 4. Presence of structural cardiac abnormalities other than patent foramen ovale (PFO), such as moderate or severe valvular regurgitation or pulmonary hypertension; 5. Presence of severe central nervous system (CNS) diseases, including acute cerebrovascular disease, intracranial tumors, intracranial infections, or progressive CNS disorders; 6. Evidence of vascular puncture site infection or difficulty with puncture as assessed by transesophageal echocardiography combined with contrast-enhanced right heart echocardiography; 7. Documented contraindications to antiplatelet therapy; 8. Presence of severe psychiatric disorders, such as schizophrenia, bipolar disorder, or severe depression or anxiety; 9. History of alcohol or other substance abuse; 10. Severe dysfunction of vital organs (heart, lungs, liver, kidneys) deemed by the investigator to pose a risk to the participant or impair the participant's ability to complete the study; 11. Pregnant or breastfeeding women, or women planning to conceive during the study period; 12. Participation in another interventional clinical trial within three months prior to signing the informed consent form, current participation in another interventional trial, or plans to participate in another interventional trial during the study period; inability to comply with follow-up due to travel or relocation; 13. Any other condition that the investigator determines makes the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage decrease in seizure frequency compared to baseline period | Week 48 | Percentage decrease in seizure frequency compared to baseline period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of decrease from baseline in Epilepsy Severity | Week 48 | Percentage of decrease from baseline in Epilepsy Severity Scale score (NHS3) |
| Percentage improvement from baseline in Quality of Life for Patients with Epilepsy | Week 48 | Percentage improvement from baseline in Quality of Life Rating Scale for Patients with Epilepsy (QOLIE-31) |
| Percentage decrease in mean duration of seizures from baseline period | Week 48 | Percentage decrease in mean duration of seizures from baseline period |
| The proportion of subjects whose seizure frequency decreased by more than 50% compared to the baseline period | Week 48 | The proportion of subjects whose seizure frequency decreased by more than 50% compared to the baseline period |
| The proportion of subjects whose average duration of epileptic seizures decreased by more than 50% compared to the baseline period | Week 48 | The proportion of subjects whose average duration of epileptic seizures decreased by more than 50% compared to the baseline period |
| The maximum number of observation days without sustained epileptic seizures during the follow-up observation period | Up to 48 weeks | The maximum number of observation days without sustained epileptic seizures during the follow-up observation period |
Other
| Measure | Time frame | Description |
|---|---|---|
| Scores of Hamilton Anxiety Scale (HAMA) | Week 24 and week 48 | The severity of anxiety |
| Incidence rate of adverse reactions | Up to 48 weeks | Incidence rate of adverse reactions |
| Scores of Hamilton Depression Scale (HAMD) | Week 24 and week 48 | The severity of depression |
| Scores of MMSE | Week 24 and week 48 | The severity of cognitive decline |
| Scores of MoCA | Week 24 and week 48 | The severity of cognitive decline |
| Scores of Headache Impact Test-6 | Week 24 and week 48 | The severity of migraine |
| Scores of Migraine-SpecificQuality-of-Life Questionnaire | Week 24 and week 48 | The severity of migraine |
| Scores of Pittsburgh Sleep Quality Index | Week 24 and week 48 | sleep quality |
Countries
China
Contacts
Primary ContactLei Chen
Outcome results
None listed